Molecular Imaging: Page 105

Study suggests extending Cu-64 tracer window to 3 hours

By Rebekah Moan

For patients with neuroendocrine neoplasms, the imaging time window of copper-64 (Cu-64) DOTATATE PET/CT can be extended from one hour to three hours after injection, according to new research.

January 24, 2021

SNMMI urges fast-track review of Technegas for V/Q scans

By Brian Casey

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has sent a letter to the U.S. Food and Drug Administration (FDA) urging the agency to begin a fast-track review of the Technegas agent for nuclear medicine ventilation/perfusion (V/Q) lung scans.

January 20, 2021

PET identifies tau's origin in Alzheimer's disease

By Erik L. Ridley

An automated PET image analysis method can track the development of tau protein clumps in the brains of people with Alzheimer's disease, revealing an important clue in how the devastating disease could potentially be treated, according to research published online January 20 in Science Translational Medicine.

January 20, 2021

Lightpoint gets CE Mark for Sensei device

By AuntMinnie.com staff writers

Luminescence imaging technology developer Lightpoint Medical has received a CE Mark for Sensei, the first robotic gamma probe to be commercially available in Europe.

January 19, 2021

ARTMS, Isotopia produce PSMA-11 in cyclotron

By AuntMinnie.com staff writers

ARTMS and Isotopia Molecular Imaging have announced the multicurie labeling of a prostate-specific membrane antigen (PSMA)-11-based radiopharmaceutical using cyclotrons.

January 19, 2021

PET shows aerobic exercise has little effect on amyloid

By Wayne Forrest

While aerobic exercise is good for the cardiovascular system, PET images show a weekly regimen of this activity does nothing to change the status of beta-amyloid buildup in older adults with elevated levels of the marker for Alzheimer's disease, according to a study published online January 14 in PLOS One.

January 19, 2021

Blue Earth eyes new uses for fluciclovine F-18

By AuntMinnie.com staff writers

Bracco molecular imaging subsidiary Blue Earth Diagnostics announced that the first patient has been dosed in a phase III clinical study examining the use of its Axumin (fluciclovine fluorine-18, F-18) PET radiopharmaceutical for detecting recurrent brain metastases.

January 14, 2021

Report charts 80% drop in cardiac SPECT during COVID-19

By Emily Hayes

A hospital in Alabama saw an 80% drop in the volume of SPECT myocardial perfusion imaging studies during the peak of the COVID-19 pandemic in spring 2020 as patients postponed nonessential procedures.

January 14, 2021

Actinium, Astellas to create actinium-225 radiotherapies

By AuntMinnie.com staff writers

Immunotherapy technology developer Actinium Pharmaceuticals will work with Astellas Pharma to develop new actinium-225 targeted radiotherapies.

January 12, 2021

AuntMinnie.com Molecular Imaging Insider

By Brian Casey

January 12, 2021

PET/CT guidance offers valuable approach to lung biopsies

By Wayne Forrest

One optimum way to reduce inconclusive lung biopsy results and better detect malignancies is to use FDG-PET/CT for the image-guided procedure. Researchers from Brazil found that PET/CT had advantages over conventional CT guidance.

January 12, 2021

Lantheus submits drug master file for imaging biomarker

By AuntMinnie.com staff writers

Lantheus Holdings, parent company of Lantheus Medical Imaging, said that it has filed a drug master file with the U.S. Food and Drug Administration for NM-01, a PD-L1 imaging biomarker for use in nuclear medicine.

January 11, 2021

Previous Page

Page 105 of 614

Next Page